TRAW

SEC filing TRAW Advances Broad-Spectrum Antiviral Agent Against Hantavirus, Ebola, Lassa Fever with Novel Dual-Strike Mechanism

6d ago

Short volume Short volume 72% of volume (6.9σ)

11d ago

News Traws Pharma GAAP EPS of -$0.53 beats by $0.03, revenue of $0M

18d ago

SEC filing TRAW Q1 2026 Losses $7.1M, $0 Revenue, EPS -$0.53

18d ago

Insider trade Purchase by ORBIMED ADVISORS LLC / Capital GP Viii Llc Orbimed

34d ago

News Traws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027

47d ago

SEC filing TRAW Announces Up to $60M Private Placement Financing Led by Sirenia Capital, Includes $10M Upfront, $10M Milestone Warrants, $30M Series C, Advances Influenza Program via UK Human Challenge Trial

48d ago

News Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

153d ago

Scanner Unusual volume (z=39.8)

166d ago

Short interest Short Interest

166d ago